George Papatheodoridis

1998–2026 年に発表

156
論文数
23,512
被引用数
84
h 指数
145
i10 指数

被引用数

George Papatheodoridis の年別被引用数1986 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 2 件2001 年: 被引用 19 件2002 年: 被引用 29 件2003 年: 被引用 35 件2004 年: 被引用 47 件2005 年: 被引用 43 件2006 年: 被引用 48 件2007 年: 被引用 67 件2008 年: 被引用 64 件2009 年: 被引用 73 件2010 年: 被引用 64 件2011 年: 被引用 80 件2012 年: 被引用 104 件2013 年: 被引用 77 件2014 年: 被引用 100 件2015 年: 被引用 117 件2016 年: 被引用 110 件2017 年: 被引用 147 件2018 年: 被引用 205 件2019 年: 被引用 706 件2020 年: 被引用 796 件2021 年: 被引用 894 件2022 年: 被引用 645 件2023 年: 被引用 612 件2024 年: 被引用 1,071 件2025 年: 被引用 595 件2026 年: 被引用 15 件1987〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,463 件、この内訳の 14.5%中国: 引用元論文 1,219 件、この内訳の 12.1%イタリア: 引用元論文 643 件、この内訳の 6.4%イギリス: 引用元論文 641 件、この内訳の 6.3%ドイツ: 引用元論文 437 件、この内訳の 4.3%フランス: 引用元論文 426 件、この内訳の 4.2%スペイン: 引用元論文 374 件、この内訳の 3.7%韓国: 引用元論文 325 件、この内訳の 3.2%台湾: 引用元論文 309 件、この内訳の 3.1%カナダ: 引用元論文 307 件、この内訳の 3%オーストラリア: 引用元論文 283 件、この内訳の 2.8%日本: 引用元論文 281 件、この内訳の 2.8%
0%14.5%その他 33.6%

分野

  • Medicine90.9%
  • Biochemistry, Genetics and Molecular Biology5.3%
  • Immunology and Microbiology1.6%
  • Neuroscience0.4%
  • Computer Science0.4%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • その他1.1%

トピック

  • Liver Disease Diagnosis and Treatment16.8%
  • Hepatitis B Virus Studies16.1%
  • Hepatitis C virus research14.9%
  • Liver Disease and Transplantation5.3%
  • Hepatitis Viruses Studies and Epidemiology4.2%
  • Hepatocellular Carcinoma Treatment and Prognosis3.8%
  • その他38.9%

共著者

全論文

検索で開く
  1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

    著者: , , , , , , , - Journal of Hepatology 2017 被引用: 5,440

  2. Hepatitis B

    著者: , , - The Lancet 2023 被引用: 540

  3. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patrick M. Bossuyt, Hadi Zafarmand, Yasaman Vali, Jenny Lee, Vlad Ratziu, Karine Clément, Raluca Pais, Detlef Schuppan, Jörn M. Schattenberg, Toni Vidal-Puig, Michèle Vacca, Sergio Rodrigues-Cuenca, Mike Allison, Ioannis Kamzolas, Evangelia Petsalaki, Matej Orešič, Tuulia Hyötyläinen, Aiden McGlinchey, José M. Mato, Óscar Millet, Jean‐François Dufour, Annalisa Berzigotti, Michael Pavlides, Stephen A. Harrison, Stefan Neubauer, Jeremy Cobbold, Ferenc E. Mózes, Salma Akhtar, Rajarshi Banerjee, Matt Kelly, Elizabeth Shumbayawonda, Andrea Dennis, Charlotte Erpicum, Manuel Romero‐Gómez, Emilio Gómez-González, Javier Ampuero, Javier Castell, Rocío Gallego‐Durán, Isabel Fernández-Lizaranzu, Rocío Montero‐Vallejo, M.A. Karsdal, Elisabeth Erhardtsen, Daniel Guldager Kring Rasmussen, Diana Julie Leeming, Mette Juul Fisker, Antonia Sinisi, Kishwar Musa, Fay Betsou, Estelle Sandt, Manuela Tonini, Elisabetta Bugianesi, Chiara Rosso, Angelo Armandi, Fabio Marra, Amalia Gastaldelli, Gianluca Svegliati, Jérôme Boursier, Sven Francque, Luisa Vonghia, Mattias Ekstedt, Stergios Kechagias, Hannele Yki‐Järvinen, Panu K. Luukkonen, Saskia W. C. van Mil, George Papatheodoridis, Helena Cortez‐Pinto, Luca Valenti, Salvatore Petta, Luca Miele, Andreas Geier ほか 35 名 - Journal of Hepatology 2021 被引用: 353

  4. An international multidisciplinary consensus statement on MAFLD and the risk of CVD

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jang Won Son, John Ryan, Ignatios Ikonomidis, Sombat Treeprasertsuk, Daniele Pastori, Monica Lupșor‐Platon, Herbert Tilg, Hasmik Ghazinyan, Jérôme Boursier, Masahide Hamaguchi, Mindie H. Nguyen, Jian‐Gao Fan, George Boon‐Bee Goh, Mamun Al Mahtab, Saeed Hamid, Nilanka Perera, Jacob George, Ming‐Hua Zheng - Hepatology International 2023 被引用: 183

  5. EASL Clinical Practice Guidelines on hepatitis delta virus

    著者: , , , , , , , , , , - Journal of Hepatology 2023 被引用: 252

  6. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yongpeng Chen, Harry L.A. Janssen, Chaonan Zhu, Lei Shi, Xiaoping Tang, Anuj Gaggar, Lai Wei, Jidong Jia, William L. Irving, Philip J. Johnson, Pietro Lampertico, Jinlin Hou - Journal of Hepatology 2020 被引用: 349

  7. Natural history of metabolic dysfunction-associated steatotic liver disease

    著者: , - European Journal of Internal Medicine 2023 被引用: 198

  8. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Hepatology 2019 被引用: 358

  9. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Hepatology 2015 被引用: 541

  10. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Hepatology 2020 被引用: 207

  11. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ajay Duseja, Adriaan G. Holleboom, Junping Shi, Wah‐Kheong Chan, Yasser Fouad, Junwei Yang, Sombat Treeprasertsuk, Helena Cortez‐Pinto, Masahide Hamaguchi, Manuel Romero‐Gómez, Mamun Al Mahtab, Ponsiano Ocama, Atsushi Nakajima, Chunsun Dai, Mohammed Eslam, Lai Wei, Jacob George, Ming‐Hua Zheng - HepatoBiliary Surgery and Nutrition 2023 被引用: 88

  12. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Myoung‐jin Jang, Yun Bin Lee, Yoon Jun Kim, Jung‐Hwan Yoon, George Papatheodoridis, Jeong‐Hoon Lee - Journal of Hepatology 2021 被引用: 145

  13. A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Linda Henry, Maria Stepanova - Clinical Gastroenterology and Hepatology 2021 被引用: 111

  14. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Stepanova - Clinical Gastroenterology and Hepatology 2021 被引用: 106

  15. Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy

    著者: , , , , - Journal of Hepatology 2015 被引用: 495

  16. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elisabetta Bugianesi, Jörn M. Schattenberg, Quentin M. Anstee - Contemporary Clinical Trials 2020 被引用: 133

  17. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion

    著者: , , , , , , , , , - Journal of Hepatology 2022 被引用: 112

  18. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2021 被引用: 187

  19. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis

    著者: , , , , - Metabolism 2016 被引用: 275

  20. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial

    著者: , , , , , , , , - British Journal Of Nutrition 2018 被引用: 164

  21. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease

    著者: , , , , , , , , , - Clinical Nutrition 2013 被引用: 222

  22. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Infectious Diseases 2019 被引用: 193

  23. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Saeed Hamid, Nilanka Perera, Khalid Alswat, Qiuwei Pan, Michelle T. Long, Isakov Va, Man Mi, Marco Arrese, Arun J. Sanyal, Shiv Kumar Sarin, Nathalie C. Leite, Luca Valenti, Philip N. Newsome, Hannes Hagström, Salvatore Petta, Hannele Yki‐Järvinen, Jörn M. Schattenberg, Marlén Castellanos, Isabelle Leclercq, Gulnara Aghayeva, Abdel‐Naser Elzouki, Ali Tumi, Ala I. Sharara, Asma Labidi, Faisal M. Sanai, Khaled Matar‎, Maen Almattooq, Maisam Akroush, Mustapha Benazzouz, Nabil Debzi, Maryam Alkhatry, Salma Barakat, Said A. Al‐Busafi, John Rwegasha, Wah Yang, Adwoa Agyei‐Nkansah, Christopher Opio, Mohammadjavad Sotoudeheian, Yu Jun Wong, Jacob George, Ming‐Hua Zheng - JHEP Reports 2024 被引用: 94

  24. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2015 被引用: 338